Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Study:

A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

Rationale:

Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.

Purpose:

This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Neurotoxicity Syndromes
Pain
Peripheral Neuropathy
Unspecified Adult Solid Tumor, Protocol Specific
Drug: duloxetine hydrochloride
Other: placebo
Phase 3

Verified by Cancer and Leukemia Group B March, 2011

Sponsored by: Cancer and Leukemia Group B
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00489411

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Placebo Control, Masking: Double-Blind, Primary Purpose: Supportive Care

Cleveland Clinic Florida - Weston
Weston, Florida 33331
United States

Ellen L. Smith, PhD, ARNP, AOCN., Study Chair
Richard L. Schilsky, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site